Results of Two Sequential Phase II Studies of Interleukin-2 (IL2) in Metastatic Renal Cell Carcinoma and Melanoma: High-Dose Continuous Intravenous IL2 Infusion and Subcutaneous IL2 Administration in Combination With Alpha Interferon. revista-de-medicina 2017, 40 (3), 6-12. https://doi.org/10.15581/021.8892.